Blockade of FTO is an effective way to sensitize AML cells to T‐cell cytotoxicity by targeting leukocyte immunoglobulin like receptor B4 (LIRB4), which alleviates tumor immune evasion in AML to some degree.90 Here, LILRB4 is linked to acute myeloid leukemia.